Newsroom | 989850 results
Sorted by: Latest
-
Yum! Brands Appoints Former Marriott International CFO Kathleen (Leeny) K. Oberg to Board
LOUISVILLE, Ky.--(BUSINESS WIRE)--Yum! Brands, Inc. (NYSE: YUM) today announced the appointment of Kathleen (Leeny) K. Oberg, former Chief Financial Officer and Executive Vice President, Development of Marriott International, Inc., to its Board of Directors, effective April 1, 2026. “Leeny is a highly accomplished leader with deep global experience and a strong track record of driving disciplined growth,” said Brian Cornell, non-executive chairman of the Yum! Brands Board of Directors. “Her exp...
-
Magnolia Oil & Gas Schedules Conference Call for First Quarter 2026 Results
HOUSTON--(BUSINESS WIRE)--Magnolia Oil & Gas Schedules Conference Call for First Quarter 2026 Results...
-
Newleos Announces Dosing of First Participant in U.K. Phase 1b Study of NTX-1955 in Generalized Anxiety Disorder
BOSTON--(BUSINESS WIRE)--Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced that the first participant has been dosed in the company’s third Phase 1b study of NTX-1955, designed to evaluate its safety and tolerability in generalized anxiety disorder (GAD). NTX-1955 is Newleos’ GABAA-γ1 positive allosteric modulator (PAM) and represents a potential first-in-class treatment for GAD. The Phase 1b study...
-
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceu...
-
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceu...
-
Novocure to Report First Quarter 2026 Financial Results
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 30, to discuss the company’s financial results for the three-month period that ended March 31, 2026. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To acces...
-
SRM Invests in Category Leadership with Appointment of Jody Guetter as Firm's Chief Marketing Officer
MEMPHIS, Tenn.--(BUSINESS WIRE)--SRM announces the appointment of Jody Guetter as Chief Marketing Officer....
-
CIBC Innovation Banking Provides Growth Capital to REG Technologies
LONDON--(BUSINESS WIRE)--CIBC Innovation Banking announced today that it has provided growth financing for REG Technologies, a leading provider of compliance and regulatory risk software for the insurance and financial services sector. This follows a recent majority investment in REG Technologies by Accel-KKR, a global tech-focused private equity firm. The company will use the financing to accelerate product innovation, build on its commercial capabilities, and expand into new international mar...
-
Orionis Biosciences Appoints Dr. Giulio Draetta as Chief Strategy Officer
BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences, a privately held, clinical‑stage life sciences company focused on discovery, design and development of precision medicines for cancer and immune system-related disorders, today announced the appointment of Dr. Giulio Draetta, M.D., Ph.D., as Chief Strategy Officer. Dr. Draetta joins Orionis at an exciting phase of growth as the company advances and broadens its portfolio across molecular glues, conditionally active cytokines, immune...
-
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers
CUYAHOGA FALLS, Ohio--(BUSINESS WIRE)--Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinat...